Posters

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Background: Satralizumab reduced relapse risk vs placebo in neuromyelitis optica spectrum disorder (NMOSD) patients and had a favourable safety profile in two phase 3 trials:...

Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to high-dose corticosteroids. Repository corticotropin injection (RCI; Acthar® Gel) is...

2021 CMSC Annual Meeting

relapse therapy

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis

MAILING ADDRESS

CONTACT US

FOLLOW US